Search - tctmd.com

Displaying 301 - 320 of 502

Sort: Relevancy | Date

News Daily News

Study Suggests Noncardiac Surgery Can Be Safe as Early as 3 Months After PCI

Yael L. Maxwell

August 20, 2014

News Daily News

Meta-analysis Confirms Advantage of New-Generation DES in STEMI

Todd Neale

August 07, 2014

News Daily News

El Impacto Clínico del Fracaso del SLF Depende del Timing

L.A. McKeown

August 07, 2014

News Daily News

Clinical Impact of DES Failure Depends on Timing

L.A. McKeown

August 07, 2014

News Daily News

Bioresorbable Scaffold Performs Well, But Thrombosis Raises Concerns

Todd Neale

July 24, 2014

News Daily News

HOST-ASSURE: Promus Element Noninferior to Resolute in All-Comers Population

July 10, 2014

News Daily News

SCAAR: Lower Risk of Early, Late Stent Thrombosis with Newer DES vs BMS in STEMI

Yael L. Maxwell

July 03, 2014

News Daily News

Nationwide Registry Shows Trends in DES Use Over a Decade

June 02, 2014

News Conference News EuroPCR 2014

BABILON: Drug-Eluting Balloon a Risky Choice for Treating Bifurcation Lesions

Caitlin E. Cox

May 21, 2014

News Daily News

Short-term DAPT After DES Decreases Bleeding with No Increase in Death, MI

May 20, 2014

News Daily News

La Terapia Antiplaquetaria Doble a Corto Plazo Post-Implantación de SLF Reduce las Hemorragias Sin un Aumento de Muerte ni IM

May 20, 2014

News Conference News EuroPCR 2014

CENTURY II: Bioresorbable Polymer DES Stands up to Everolimus-Eluting Device

Caitlin E. Cox

May 20, 2014

News Daily News

Long-term Outcomes of ‘Full Metal Jacket’ Stenting Appear Favorable

April 30, 2014

News Daily News

Drug-Eluting Balloon Provides Strong Primary Patency in SFA at 1 Year

April 14, 2014

News Daily News

Cardiac Rehab Reduces Late Lumen Loss, Improves Risk Profile in Patients with Long Lesions

April 14, 2014

Presentation Fellows 2014

Drug-Eluting Stents: Past, Present, and Future

Presenter: Gregg Stone

April 12, 2014

News Daily News

Registry: DAPT Discontinuation Less Associated With Second-Gen DES Thrombosis Compared to First-Gen DES

L.A. McKeown

April 11, 2014

Presentation ACC 2014

Two-Year Outcome of a Randomized Trial Comparing Second Generation Drug-eluting Stents Using Either Biodegradable Polymer or Durable Polymer

Presenter: Masahiro Natsuaki

March 31, 2014

News Conference News ACC 2014

ZES Plus Tailored Course of Dual Therapy Reduces Adverse Events in Unlikely DES Candidates

Yael L. Maxwell

March 31, 2014

News Conference News ACC 2014

NEXT at 2 Years: Nobori DES Still Noninferior to Xience/Promus

Jason Kahn

March 31, 2014

Advertisement

Study Suggests Noncardiac Surgery Can Be Safe as Early as 3 Months After PCI

Meta-analysis Confirms Advantage of New-Generation DES in STEMI

El Impacto Clínico del Fracaso del SLF Depende del Timing

Clinical Impact of DES Failure Depends on Timing

Bioresorbable Scaffold Performs Well, But Thrombosis Raises Concerns

HOST-ASSURE: Promus Element Noninferior to Resolute in All-Comers Population

SCAAR: Lower Risk of Early, Late Stent Thrombosis with Newer DES vs BMS in STEMI

Nationwide Registry Shows Trends in DES Use Over a Decade

BABILON: Drug-Eluting Balloon a Risky Choice for Treating Bifurcation Lesions

Short-term DAPT After DES Decreases Bleeding with No Increase in Death, MI

La Terapia Antiplaquetaria Doble a Corto Plazo Post-Implantación de SLF Reduce las Hemorragias Sin un Aumento de Muerte ni IM

CENTURY II: Bioresorbable Polymer DES Stands up to Everolimus-Eluting Device

Long-term Outcomes of ‘Full Metal Jacket’ Stenting Appear Favorable

Drug-Eluting Balloon Provides Strong Primary Patency in SFA at 1 Year

Cardiac Rehab Reduces Late Lumen Loss, Improves Risk Profile in Patients with Long Lesions

Drug-Eluting Stents: Past, Present, and Future

Registry: DAPT Discontinuation Less Associated With Second-Gen DES Thrombosis Compared to First-Gen DES

Two-Year Outcome of a Randomized Trial Comparing Second Generation Drug-eluting Stents Using Either Biodegradable Polymer or Durable Polymer

ZES Plus Tailored Course of Dual Therapy Reduces Adverse Events in Unlikely DES Candidates

NEXT at 2 Years: Nobori DES Still Noninferior to Xience/Promus

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content